

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
10 April 2025 (10.04.2025)



(10) International Publication Number
WO 2025/073004 A1

(51) International Patent Classification:

A61K 31/191 (2006.01) *A61K 35/747* (2015.01)
A61K 9/00 (2006.01) *A61K 47/38* (2006.01)
A61K 9/06 (2006.01) *A61P 15/02* (2006.01)
A61K 31/4164 (2006.01) *A61P 29/00* (2006.01)
A61K 35/00 (2006.01)

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(21) International Application Number:

PCT/AU2024/051048

(22) International Filing Date:

04 October 2024 (04.10.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2023903187 04 October 2023 (04.10.2023) AU

(71) Applicant: **MACFARLANE BURNET INSTITUTE
FOR MEDICAL RESEARCH AND PUBLIC HEALTH
LIMITED** [AU/AU]; 85 Commercial Road, Melbourne,
Victoria 3004 (AU).

(72) Inventor: **TACHEDJIAN, Gilda**; c/o Macfarlane Burnet
Institute for Medical Research and Public Health Limited,
85 Commercial Road, Melbourne, Victoria 3004 (AU).

(74) Agent: **FB RICE PTY LTD**; Level 33, 477 Collins St, Mel-
bourne, Victoria 3000 (AU).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: VAGINAL COMPOSITIONS AND METHODS AND USES THEREOF

(57) Abstract: The present invention relates to a vaginal pharmaceutical composition and the methods and uses thereof including: treating and preventing genital inflammation in a subject; modifying the level of one or more of *Lactobacillus crispatus*, *Lactobacillus gasseri*, *Lactobacillus Gardnerella*, *Lactobacillus jensenii* and *Lactobacillus iners* in the genital microbiome of a subject; and main-
taining or increasing the integrity of the cervicovaginal epithelial barrier in a subject.

WO 2025/073004 A1